NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A Meeting Minutes

**Minutes:** Confirmed

**Date:** Tuesday 7 September 2021

**Location:** Via Zoom Teleconference

## Attendees

Committee members present

1. Dr Jane Adam (chair) Present for all Items
2. Dr Brian Shine (vice-chair) Present for all Items
3. Prof. Abdallah Al-Mohammad Present for all Items
4. Richard Ballerand Present for all Items
5. Dr Craig Buckley Present for all Items
6. Andrew Champion Present for all Items
7. Ana Duarte Present for all Items
8. Dr Steve Edwards Present for all Items
9. Dr Michael Holmes Present for all Items
10. Prof. Khalida Ismail Present for all Items
11. Dr Fiona MacPherson Smith Present for all Items
12. Dr David Maudgil Present for all Items
13. Prof. G.J. Melendez-Torres Present for all Items
14. Hugo Pedder Present for all Items
15. Dominic Pivonka Present for all Items
16. Dr Mohit Sharma Present for all Items
17. Min Ven Teo Present for all Items
18. Dr Roger Whittaker Present for all Items

NICE staff present

Janet Robertson, Associate Director Present for all Items

Thomas Feist, Project Manager Present for all Items

Lorna Dunning, Health Technology Assessment Adviser Present for all Items

Summaya Mohammad, Health Technology Assessment Analyst Present for all Items

Sarah Bromley, Senior Medical Editor Present for all Items

Claire Hawksworth, Technical Analyst, Evidence Generation Items 4.1.3 to 4.2.2

Stevie Okoro, Technical Analyst, Commercial Risk Assessment Present for all Items

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.1.3

Gemma Smith, Coordinator, COT Present for all Items

Marcia Miller, Administrator, TA Present for all Items

James Devine, Coordinator, COT Present for all Items

External review group representatives present

Matt Stevenson, School of Health and Related Research (ScHARR) Items 1 to 4.1.3

Emma Simpson, School of Health and Related Research (ScHARR) Items 1 to 4.1.3

Clinical and patient experts present

Professor Peter Clark, National Clinical lead for Cancer drugs, NHS England, Present for all Items

David Chuter, Patient expert nominated by Guts UK, Items 1 to 4.1.3

Professor Somnath Mukherjee, Consultant Clinical Oncologist, clinical expert nominated by NCRI-ACP-RCP-RCR, Items 1 to 4.1.3

Professor Anne Thomas, Professor of Cancer Therapeutics, clinical expert nominated by BMS, Items 1 to 4.1.3

## Minutes

### Introduction to the Meeting

* 1. The chair Dr Jane Adam welcomed members of the committee and other attendees to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 3 August 2021.

### Appraisal of nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (ID1676)

* 1. Part 2a – Closed Session (No public in attendance)
		1. The chair welcomed the invited clinical and patient experts, external review group representatives, the national clinical lead for cancer drugs fund, and company representatives from BMS.
		2. The chair asked all committee members, clinical and patient experts, the national clinical lead for cancer drugs fund, external review group representatives and NICE staff present to declare any relevant Interests in relation to the item being considered.
* Committee member Professor Abdallah Al-Mohammad declared financial interests as he has attended advisory boards regarding PARAGON-HF with Novartis in October 2019 and iv iron in Heart Failure with Pharmacosmos January 2021, He has received honoraria for talks from AstraZeneca July 2020, Janssen October 2020 and Takeda January 2021 and his department received a small grant from AstraZeneca in December 2020 for purchase of blood pressure machines for HF patients to allow uptitration of drugs remotely
* It was agreed that his declarations would not prevent Professor Al-Mohammad from participating in this section of the meeting.
* Nominated clinical expert Professor Somnath Mukherjee declared non-financial and indirect interests as she is a Co-investigator on the LUD2015-005 trial (a phase I trial evaluating durvalumab in combination with chemotherapy and chemoradiotherapy in metastatic and operable oesophageal cancer) and is also a member of Oesophago-gastric subgroup of NCRI Clinical Studies group (i.e.) representing Upper GI CSG of NCRI).
* It was agreed that his declarations would not prevent Professor Mukherjee from providing expert advice to the committee.
* No further conflicts were declared for this Item.
	+ 1. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Min Ven Teo and Dr Brian Shine.
	1. Part 2b – Closed session (company representatives, clinical and patient experts and external review group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) In line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 5 October 2021 and will start promptly at 9.30am.